Literature DB >> 2306726

Nonlinear pharmacokinetics of CPT-11 in rats.

N Kaneda1, T Yokokura.   

Abstract

The pharmacokinetics of a new water-soluble derivative of camptothecin. 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11), and its major metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), was investigated after i.v. administration of 1 to 40 mg/kg of CPT-11 to rats. The plasma concentration of CPT-11 decreased biexponentially. The area under the concentration-time curve increased nonlinearly as the dose increased. SN-38 was found in the plasma, bile, urine, and feces. The SN-38 level was maintained at 0.06 to 0.08 micrograms/ml for 0.5 to 5.5 h depending on the dose, followed by exponential decay. Thirty-three to 58% of the CPT-11 was excreted without metabolism into the bile and urine for 24 h. SN-38 was mainly excreted into the bile. Analysis of the clearance has shown nonlinear pharmacokinetics which was due to metabolic processes such as the conversion of CPT-11 to SN-38.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2306726

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats.

Authors:  Masato Horikawa; Yukio Kato; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

2.  Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11.

Authors:  T Miya; T Goya; H Fujii; T Ohtsu; K Itoh; T Igarashi; H Minami; Y Sasaki
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

3.  Old drug new use--amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity.

Authors:  Ren Kong; Timothy Liu; Xiaoping Zhu; Syed Ahmad; Alfred L Williams; Alexandria T Phan; Hong Zhao; John E Scott; Li-An Yeh; Stephen T C Wong
Journal:  Clin Cancer Res       Date:  2014-04-29       Impact factor: 12.531

4.  Development and validation of an UPLC-MS/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: Application to a pharmacokinetic study of irinotecan in rats.

Authors:  Sumit Basu; Min Zeng; Taijun Yin; Song Gao; Ming Hu
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-02-09       Impact factor: 3.205

5.  Ugt1a is required for the protective effect of selenium against irinotecan-induced toxicity.

Authors:  Shousong Cao; Farukh A Durrani; Youcef M Rustum; Y Eugene Yu
Journal:  Cancer Chemother Pharmacol       Date:  2012-01-12       Impact factor: 3.333

Review 6.  The human microbiome is a source of therapeutic drug targets.

Authors:  Bret D Wallace; Matthew R Redinbo
Journal:  Curr Opin Chem Biol       Date:  2013-05-13       Impact factor: 8.822

7.  Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan.

Authors:  L P Rivory; J Robert
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine.

Authors:  F Lokiec; P Canal; C Gay; E Chatelut; J P Armand; H Roché; R Bugat; E Gonçalvès; A Mathieu-Boué
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 9.  Vinorelbine and the topoisomerase 1 inhibitors: current and potential roles in breast cancer chemotherapy.

Authors:  S O'Reilly; M J Kennedy; E K Rowinsky; R C Donehower
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

10.  CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein.

Authors:  W J Jansen; T M Hulscher; J van Ark-Otte; G Giaccone; H M Pinedo; E Boven
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.